Jay S. Skyler, M.D.
- Fax: 305-585-8655
- American Board of Internal Medicine
- American Bd of Int Med-Endocrinology Diabetes & Metabolism
- Internal Medicine
- Endocrinology, Diabetes and Metabolism
- Associate Director, Diabetes Research Institute
- Chairman, Type 1 Diabetes TrialNet Clinical Trials Network
- Professor of Medicine, Pediatrics, & Psychology
Immunology of type 1 diabetes, type 1 diabetes prevention, prevention of diabetic complications, new forms of therapy for diabetes
Duke University Medical Center
Duke University Medical Center
Jefferson Medical College
Pennsylvania State University
Jay S. Skyler, MD, MACP is currently a Professor of Medicine, Pediatrics, & Psychology, in the Division of Endocrinology, Diabetes, & Metabolism, Department of Medicine, University of Miami Leonard M. Miller School of Medicine, Miami, Florida . He served as Director of that Division from 2000 to 2004. He is Associate Director for Academic Programs in the Diabetes Research Institute, University of Miami . He was also Program Director of the UM's General Clinical Research Center (GCRC) from 2001 to 2006. He was chairman of the Planning Committee for the University's new Clinical Research Institute, a 336,000 square foot facility which will opened in 2006. He is Chairman of the NIH (NIDDK)-sponsored Type 1 Diabetes TrialNet, a nationwide network conducting clinical trials to interdict type 1 diabetes.
A native of Philadelphia, Dr. Skyler is a graduate of Penn State University and Jefferson Medical College, and did his postgraduate training in Internal Medicine and in Endocrinology and Metabolism at Duke University Medical Center. He also was on the faculty at Duke, where he was Director of Diabetes & Nutrition Education and Medical Director of the Physician's Associate Program, and was named an Honorary Physician's Associate in recognition of distinguished teaching. He worked two years at the Hypertension-Endocrine Branch (Section on Biochemical Pharmacology) of the National Heart and Lung Institute, National Institutes of Health. He joined the University of Miami in 1976.
Dr. Skyler's career in diabetes spans nearly four decades, beginning as a medical student in 1967. For 13 summers, he served as director of a diabetes summer camp, where he became recognized for using camp as a locus for training of medical and nursing students, house staff, and fellows. At the University of Miami, he initiated and for 10 years served as Director of the Diabetes Metabolic Unit. During his tenure as Director, that unit attained national and international prominence, being selected as the model diabetes unit to represent the at the Worldwide Diabetes Care Program held in conjunction with the 12th International Diabetes Federation (IDF) Congress in Madrid in 1985.
His research interests are in clinical aspects of diabetes, particularly improving the care of Type 1 diabetes through meticulous glycemic control, psychosocial and behavioral support, and immune intervention. He was Study Chairman for the nationwide multicenter Diabetes Prevention Trial for Type 1 Diabetes (DPT-1) and currently is Study Chairman of its successor Type 1 Diabetes TrialNet. He has long been interested in the complications of diabetes, and in the relationship between blood pressure and blood glucose. Dr. Skyler was a pioneer in the use of patient self-monitoring of blood glucose and in developing the concept of “Intensive Insulin Therapy.” He is widely acclaimed for his “algorithms” for patient adjustment of insulin doses. For these contributions, Dr. Skyler received the 1985 Achievement Award of the American Society of Contemporary Medicine & Surgery “for Distinguished Contributions to the Knowledge of Diabetes Mellitus”. He gave a plenary lecture and received the Plenary Medal at the 13th IDF Congress in Sydney in 1988, and gave a plenary lecture and received a Plenary Plaque at the 15th IDF Congress in Kobe in 1994.
Much of Dr. Skyler's current research focus is in interdicting the type 1 diabetes disease process through immunoregulation. Beginning in the 1980s, he and his colleagues conducted some of the first research using cyclosporine as immune intervention and demonstrated that this resulted in sustained beta-cell function. Later, he designed and served as Study Chairman for the nationwide multicenter NIH-sponsored Diabete